Boehringer Ingelheim presented positive results of its Phase 3 RE-VERSE AD study for idarucizumab as a reversal agent for the anticoagulant effect of Pradaxa (dabigatran) in patients needing emergency surgery or for life-threatening or uncontrolled bleeding events.
Regeneron and Sanofi announced new positive results for Praluent (alirocumab) from the Phase 3 ODYSSEY clinical trial program in heterozygous familial hypercholesterolemia (HeFH) patients.
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Empliciti (elotuzumab, Bristol-Myers Squibb/AbbVie) for the treatment of multiple myeloma as combination therapy in patients who have received one or more prior therapies.
Results from the PATHWAY 3 study demonstrated that a combination of half-dose diuretics can significantly reduce blood pressure without the adverse effects associated with full doses of either diuretic alone, as reported at the European Society of Cardiology Congress 2015.
Newer genetic tests like chromosomal microarray analysis and whole-exome sequencing for children with autism spectrum disorder (ASD) may help detect genetic mutations potentially associated to the disorder, a study published in JAMA reported.